Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00814983 | Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft | terminated | Phase 1 / Phase 2 | 15 | Duke UniversityOTHER | 0 | Nov 25, 2013 | clinicaltrials |
| NCT01500161 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | terminated | Phase 2 | 1 | Texas Oncology Cancer CenterINDUSTRY | 1 | Nov 25, 2013 |
| NCT00718640 | An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function | terminated | Phase 2 | 10 | Janssen-Ortho Inc., CanadaINDUSTRY | 1 | Oct 29, 2013 | clinicaltrials |
| NCT00058461 | Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | terminated | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00243035 | Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00072449 | Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma | terminated | Phase 2 | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2013 | clinicaltrials |
| NCT00241371 | A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 8 | Washington University School of MedicineOTHER | 1 | Aug 13, 2013 | clinicaltrials |
| NCT00104819 | Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma | terminated | Phase 2 | 238 | FavrilleINDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00079443 | FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2013 | clinicaltrials |
| NCT01617213 | Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma(AMM-2011) | terminated | Phase 2 | 1 | University of VirginiaOTHER | 1 | Jun 21, 2013 | clinicaltrials |
| NCT00009984 | Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer | terminated | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00493454 | Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | May 31, 2013 | clinicaltrials |
| NCT00126191 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | terminated | Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | May 23, 2013 | clinicaltrials |
| NCT00393380 | Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor | terminated | Phase 2 | 13 | The Emmes Company, LLCINDUSTRY | 1 | Apr 29, 2013 | clinicaltrials |
| NCT01179490 | Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma | terminated | Phase 2 | 5 | SymBio PharmaceuticalsINDUSTRY | 1 | Mar 18, 2013 | clinicaltrials |
| NCT01667289 | Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma | terminated | Phase 2 | 4 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT00006220 | Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy | terminated | Phase 1 / Phase 2 | 5 | Washington University School of MedicineOTHER | 1 | Feb 6, 2013 | clinicaltrials |
| NCT00452127 | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 26 | Genentech, Inc.INDUSTRY | 0 | Jan 28, 2013 | clinicaltrials |
| NCT00015912 | Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00086840 | CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | terminated | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00005950 | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma | terminated | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00005982 | 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00052377 | Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00301795 | Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | terminated | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00902525 | Zevalin Twice in Aggressive Non-Hodgkin Lymphoma | terminated | Phase 2 | 25 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle LeucemieOTHER | 1 | Dec 31, 2012 | clinicaltrials |
| NCT00727207 | Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy | terminated | Phase 2 | 35 | Technical University of MunichOTHER | 1 | Dec 17, 2012 | clinicaltrials |
| NCT00850499 | Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab | terminated | Phase 2 | 12 | Millennium Pharmaceuticals, Inc.INDUSTRY | 7 | Dec 12, 2012 | clinicaltrials |
| NCT00005852 | Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant | terminated | Phase 2 | — | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Dec 11, 2012 | clinicaltrials |
| NCT00361621 | Ph II CHOP+Velcade in Mediastinal LBCL | terminated | Phase 2 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 3, 2012 | clinicaltrials |
| NCT00636155 | EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 20 | David RizzieriOTHER | 1 | Nov 28, 2012 | clinicaltrials |
| NCT00699296 | Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma | terminated | Phase 2 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 27, 2012 | clinicaltrials |
| NCT00742495 | Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.(BCX1777-108) | terminated | Phase 1 / Phase 2 | 2 | Mundipharma Research LimitedINDUSTRY | 6 | Oct 24, 2012 | clinicaltrials |
| NCT00060385 | Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma | terminated | Phase 2 / Phase 3 | 3 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Sep 24, 2012 | clinicaltrials |
| NCT00793650 | Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study | terminated | Phase 1 / Phase 2 | 39 | Emory UniversityOTHER | 1 | Aug 30, 2012 | clinicaltrials |
| NCT00968331 | Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | terminated | Phase 2 | 25 | University of BolognaOTHER | 1 | Aug 27, 2012 | clinicaltrials |
| NCT01036399 | Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients | terminated | Phase 2 | 9 | University of BolognaOTHER | 1 | Aug 27, 2012 | clinicaltrials |
| NCT00242827 | Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma | terminated | Phase 2 | — | CephalonINDUSTRY | 1 | Aug 23, 2012 | clinicaltrials |
| NCT00453193 | Alemtuzumab and Pentostatin In T-cell Neoplasms | terminated | Phase 2 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00810576 | Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00843050 | A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 13 | Piramal Enterprises LimitedINDUSTRY | 2 | Jul 27, 2012 | clinicaltrials |
| NCT00368121 | EMMA-1 (Erbitux for Multiple Myeloma)(EMMA-1) | terminated | Phase 2 | 13 | Prof. Dr. Andreas EngertOTHER | 1 | Jul 13, 2012 | clinicaltrials |
| NCT00208975 | Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab | terminated | Phase 2 | 15 | Emory UniversityOTHER | 1 | Jun 28, 2012 | clinicaltrials |
| NCT00005595 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease | terminated | Phase 2 | 2 | Northwestern UniversityOTHER | 1 | Jun 11, 2012 | clinicaltrials |
| NCT00004106 | Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome | terminated | Phase 2 | 29 | Northwestern UniversityOTHER | 1 | Jun 6, 2012 | clinicaltrials |
| NCT00005788 | Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome | terminated | Phase 2 | — | Northwestern UniversityOTHER | 1 | Jun 6, 2012 | clinicaltrials |
| NCT00128921 | Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 18 | University of ArkansasOTHER | 1 | Apr 26, 2012 | clinicaltrials |
| NCT00366106 | Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma | terminated | Phase 2 | 32 | Accelerated Community Oncology Research NetworkOTHER | 1 | Apr 6, 2012 | clinicaltrials |
| NCT00121186 | S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma | terminated | Phase 2 | 1 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 3, 2012 | clinicaltrials |
| NCT00827099 | Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer | terminated | Phase 2 | 5 | Northside Hospital, Inc.OTHER | 1 | Mar 23, 2012 | clinicaltrials |
| NCT00475332 | Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar | terminated | Phase 2 | 2 | University of FloridaOTHER | 1 | Feb 15, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Nov 25, 2013source: clinicaltrials